 |
 |
 |
 |
 |
|
|
Contact | Print version | PDF version | Recommend company
|
14200 Shady Grove Road 20850 Rockville, MD
United States of America
|
|
Portrait The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, cancer and other immune-mediated diseases. The Company’s primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon® (albinterferon alfa-2b) for hepatitis C and LymphoStat-B® (belimumab) for lupus. Phase 3 clinical trials of both drugs are ongoing.
Industrial Sectors
Additional information
Human Genome Sciences Rockville, MD, United States of America
News
|
|
|
|
|
|